XENETIC BIOSCIENCES, INC. Cash
XENETIC BIOSCIENCES, INC. (XBIO) had Cash of $7.35 million as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:Cash · last filed 2026-05-12
- 2026-03-31: Cash $7.35M.
- 2025-12-31: Cash $7.88M.
- 2025-03-31: Cash $5.16M.
- 2024-12-31: Cash $6.17M.
| Period end | Cash |
|---|---|
| 2026-03-31 | $7.35M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $7.88M 10-Q · filed 2026-05-12 |
| 2025-03-31 | $5.16M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $6.17M 10-Q · filed 2025-05-13 |
| 2024-09-30 | $6.84M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $7.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $7.82M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $8.98M 10-K · filed 2025-03-18 |
| 2023-09-30 | $9.78M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $10.73M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $11.99M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $13.10M 10-K · filed 2024-03-21 |
| 2022-09-30 | $13.85M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $14.93M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $16.16M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $18.24M 10-K · filed 2023-03-22 |
| 2021-09-30 | $19.70M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $9.28M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $10.01M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $11.53M 10-K · filed 2022-03-22 |
| 2020-09-30 | $7.05M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $8.07M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $9.37M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $10.37M 10-K · filed 2021-03-16 |
| 2019-09-30 | $12.04M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.03M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $2.02M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $571.61K 10-K · filed 2020-03-26 |
| 2018-09-30 | $1.61M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $3.26M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $3.87M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $5.53M 10-K · filed 2019-03-29 |
| 2017-09-30 | $694.75K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $2.33M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $4.32M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $4.05M 10-K · filed 2018-03-30 |
| 2016-09-30 | $211.90K 10-Q · filed 2017-11-14 |
| 2016-06-30 | $240.79K 10-Q · filed 2017-08-14 |
| 2016-03-31 | $1.61M 10-Q · filed 2017-05-15 |
| 2015-12-31 | $132.23K 10-K · filed 2018-03-30 |
| 2015-09-30 | $1.25M 10-Q · filed 2016-11-14 |
| 2015-06-30 | $301.48K 10-Q · filed 2016-08-15 |
| 2015-03-31 | $936.59K 10-Q · filed 2016-05-16 |
| 2014-12-31 | $2.51M 10-K · filed 2017-03-31 |
| 2014-09-30 | $4.83M 10-Q · filed 2015-11-16 |
| 2014-06-30 | $7.61M 10-Q · filed 2015-08-19 |
| 2014-03-31 | $10.86M 10-Q · filed 2015-05-20 |
| 2013-12-31 | $4.84M 10-K · filed 2016-03-30 |
| 2013-11-30 | $40.08K 10-Q · filed 2014-01-10 |
| 2013-09-30 | $6.93M 10-Q · filed 2014-11-14 |
| 2013-08-31 | $53.22K 10-Q · filed 2014-01-10 |
| 2013-06-30 | $8.73M 10-Q · filed 2014-08-14 |
| 2013-05-31 | $62.18K 10-Q · filed 2013-07-17 |
| 2013-03-31 | $9.54M 10-Q · filed 2014-05-20 |
| 2013-02-28 | $44.98K 10-Q · filed 2013-04-22 |
| 2012-12-31 | $11.14M 10-K · filed 2015-07-20 |
| 2012-11-30 | $32.01K 10-Q · filed 2014-01-10 |
| 2012-08-31 | $32.01K 10-Q · filed 2014-01-10 |
| 2012-05-31 | $33.06K 10-Q · filed 2013-07-17 |
| 2012-02-29 | $11.36K 10-Q · filed 2013-04-22 |
| 2011-12-31 | $17.12M 10-K · filed 2015-07-20 |
| 2011-11-30 | $8.18K 10-Q · filed 2013-01-22 |
| 2011-08-31 | $10.00K 10-K · filed 2013-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |